



Glioblastoma: Current Status and Future Prospects

Guest Editor:

Dr. Jason K. Sa

Department of Biomedical
Sciences, Korea University
College of Medicine, Seoul 02841,
Republic of Korea

Deadline for manuscript
submissions:

31 July 2024

Message from the Guest Editor

Dear Colleagues,

Glioblastoma (GBM) is the most common and lethal primary brain tumor in adults. Despite aggressive treatment modality, the current standard treatment regimen only provides palliation with a median survival of less than 15 months and a 5-year survival rate of 5% after initial diagnosis. However, in recent years, there has been an emergence of large interest in the development of targeted therapies for glioblastoma owing to its profound levels of genomic aberrations. Major molecular-mediated therapeutic approaches consist of targeting various oncogenic pathway-encoding molecules, including EGFR, PI3K/AKT/mTOR, VEGF, MET, FGFR, BRAF, cell cycle, and TGF β . On the other hand, immunotherapies focus on the disruption of immune checkpoint molecules that are expressed in T cells or tumor cells, such as PD-1, PD-L1, CTLA-4, LAG-3, TIM3, and TIGIT. Given the complexity of genomic architecture and microenvironment composition in GBM, future target-mediated investigations could open up new opportunities for innovative treatments.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)